Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Vaccine Clear all
Completed No phase listed Observational

"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"

NCT01309568
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Quidel Corporation
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
16
States / cities
Carlsbad, California • Panorama City, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

H3N2 M2SR in Pediatric Population

NCT03553940
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

NCT00958243
View directory record Official record
Conditions
Influenza
Interventions
CSL's 2009 H1N1 Influenza Vaccine (CSL425), Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 9 Years
Enrollment
473 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
13
States / cities
Chandler, Arizona • Melbourne, Florida • Bardstown, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

H1N1v Virus Challenge Study in Healthy Subjects

NCT04044352
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/Bethesda/MM2/H1N1 Challenge
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 14, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vaccine Efficacy in Diabetic and Elderly Patients

NCT02675608
View directory record Official record
Conditions
Inflammation
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 14, 2026, 4:17 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Durability of Vaccine Responses

NCT05801978
View directory record Official record
Conditions
Vaccine Response
Interventions
Live Attenuated Yellow Fever 17D Vaccine, Quadrivalent seasonal influenza vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View directory record Official record
Conditions
Influenza Disease; Flu
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 14, 2026, 4:17 PM EDT
Not listed Phase 4 Interventional

Optimizing Influenza Vaccination in Surgical Oncology Patients

NCT01698177
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 14, 2026, 4:17 PM EDT
Completed No phase listed Observational

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

NCT05268939
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B, RSV Infection
Interventions
LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

NCT05606965
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

NCT03143101
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
12
States / cities
Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777
View directory record Official record
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

NCT00311727
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age

NCT01997450
View directory record Official record
Conditions
Influenza Vaccine Effectiveness
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
4,121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
8
States / cities
Gainesville, Florida • Bloomington, Minnesota • Winston-Salem, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 14, 2026, 4:17 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response Following Seasonal Influenza Vaccination

NCT03163342
View directory record Official record
Conditions
Influenza
Interventions
Licensed seasonal influenza vaccine
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

NCT00539864
View directory record Official record
Conditions
Influenza
Interventions
FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years to 64 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Fresno, California • Hayward, California • Roseville, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.

NCT07386509
View directory record Official record
Conditions
Healthy
Interventions
Fluad® and Afluria® vaccination
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 49 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication

NCT06626321
View directory record Official record
Conditions
Behavior, Health, Flu, Flu Vaccination
Interventions
Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback, High risk bidirectional pre-visit text messaging
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
26,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Influenza Vaccinations

NCT06518577
View directory record Official record
Conditions
Influenza
Interventions
Flucelvax® (ccIIV3), Flublok® (RIV3)
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 64 Years
Enrollment
606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated Not applicable Interventional Results available

STIP: Statin Trial for Influenza Patients

NCT00970606
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
Interventions
Rosuvastatin (crestor), Placebo
Drug
Lead sponsor
Gordon Bernard
Other
Eligibility
13 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

NCT01857206
View directory record Official record
Conditions
Influenza, Fever
Interventions
Mammalian cell based flu vaccine, Egg based flu vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 17 Years
Enrollment
2,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
18
States / cities
Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 14, 2026, 4:17 PM EDT
Not listed Not applicable Interventional

Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease

NCT00932711
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Educational brochures
Behavioral
Lead sponsor
VA Midwest Health Care Network
Federal
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2009 · Synced Oct 14, 2026, 4:17 PM EDT